Oppenheimer & Co’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Oppenheimer & Co’s Portfolio GNOM Stock Details GNOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,444	Closed	-$273K	–	1518
2021 Q4	$273K	Sell	3,444 -5,296	-61%	-$445K	﹤0.01%	1267
2021 Q3	$774K	Buy	8,740 +2,853	+48%	+$267K	0.01%	835
2021 Q2	$586K	Buy	+5,887	New	+$522K	0.01%	953

Other funds holding GNOM

PAG

Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

MIG

McGuire Investment Group Wakefield, Rhode Island $885M AUM 47.78% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

OCM

One Capital Management Westlake Village, California $3.65B AUM 15.32% 1-Year Est. Return

MML Investors Services Springfield, Massachusetts $36.1B AUM 19.68% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

EWM

Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return

Oppenheimer & Co's GNOM Position: Q1 2022 in Review

Oppenheimer & Co sold out of Global X Genomics & Biotechnology ETF (GNOM) in Q1 2022, closing a stake of 3,444 shares — an estimated $273K sold.

Oppenheimer & Co first reported a position in GNOM in Q2 2021 and held it in 3 quarters. The position peaked at $774K in Q3 2021. 60 funds tracked by Wall St. Rank hold GNOM as of Q1 2022.

Oppenheimer & Co reported no remaining Global X Genomics & Biotechnology ETF position as of Q1 2022 after selling out during the quarter.
Oppenheimer & Co sold 3,444 Global X Genomics & Biotechnology ETF shares in Q1 2022, an estimated $273K.
Oppenheimer & Co first reported a position in Global X Genomics & Biotechnology ETF in Q2 2021 and held it in 3 quarters.
Oppenheimer & Co's Global X Genomics & Biotechnology ETF position peaked at $774K in Q3 2021.
60 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q1 2022.

Based on Oppenheimer & Co's 13F filing for Q1 2022, filed 12 May 2022.